LATE-BREAKING RESEARCH SESSION
AT THE AACR ANNUAL MEETING
Tuesday, April 23, 1996

One hour has been set aside for the presentation of about 4 definitive reports of highly
significant and timely findings in the field. Criteria for the selection of these presentations
and instructions for submission of abstracts are as follows:

INSTRUCTIONS FOR SUBMISSION OF LATE-BREAKING ABSTRACTS

1. The work to be presented must be of major novelty and significance, e.g., the
characterization of a new gene in familial cancer, and should not have been previously
published in a peer-reviewed scientific journal or presented at a national meeting.

2. The abstract must be sponsored by an AACR member in good standing (dues paid for
1996).

3. Each member in good standing may sponsor only one abstract for this session whether
or not he or she sponsored an abstract last December for the regular annual meeting
program. If an associate member is the sponsor, the abstract must also be endorsed by
an active or corresponding member in good standing. In this case, the endorser does not
forfeit the opportunity to sponsor a late-breaking abstract.

4. Abstracts must be typed on one side of one sheet of white paper.

5. All text on the page must fit within an area 6 1/2" wide and 9" high (16.5 cm X 22.9 cm)
with margins of at least 1" (2.5 cm) on the top, bottom, and sides of the page.

6. Each abstract must be accompanied by a covering letter from the sponsor explaining why
the work is novel and significant enough to be considered for this late-breaking research
session and certifying that the findings became available after the annual meeting abstract
deadline of December 1, 1995. This letter must contain the sponsor's complete mailing
address, FAX number, and Email address (if available) so that we can communicate the
scheduling decision of the Program Committee.

7. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern
Time on March 15, 1996. FAX transmissions are not acceptable. Carrying envelopes
should be clearly marked "Late-Breaking Abstract," and should be addressed to American
Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence
Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt
of your abstract, enclose a self-addressed post card with appropriate postage affixed.
Accepted abstracts will not be published since they will be received after the Proceedings
of the American Association for Cancer Research has been printed; however, they will be
distributed at the session in Washington.

8. A special subcommittee of the Program Committee appointed by President Joseph R.
Bertino will select the papers to be presented. Presenters of accepted papers will be notified
via FAX no later than March 29, 1996.
Notice to Members of the American Association for Cancer Research
Officers for 1995–1996
President: Joseph R. Bertino, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
President Elect: Louise C. Strong, UT M. D. Anderson Cancer Center, Houston, TX 77030
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AOCR, Public Ledger Bldg., Suite 816, Philadelphia, PA 19106-3483

Annual Dues
The annual dues of active members of the American Association for Cancer Research are $160, $40 of which may be applied to a subscription to Clinical Cancer Research. Corresponding members of the Association will be charged an appropriate fee to offset second-class postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, American Association for Cancer Research, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Telephone: (215) 440-9300; FAX: (215) 440-9313.

Submission of Manuscripts
Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients. All submissions undergo peer review. Papers should be sent to John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; Telephone: (212) 639-5878; FAX: (212) 717-3629.

Back Issues and Single Copy Sales of the Journal
Copies of back stock of the journal may be ordered from Clinical Cancer Research, P.O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997 or (201) 627-2427; FAX: (201) 627-5872]. As long as supplies permit, single copies will be sold by this company at $12.50/copy. Orders outside the U.S. add $3/copy to offset postage costs.

Advertisements
Advertisement insertion orders and copy must be received one month prior to the date of issue in which the advertisement is to be published. The journal is mailed on approximately the 1st day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 155 South White Horse Pike, Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Copyright and Permissions
Authors who wish to publish in Clinical Cancer Research must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AOCR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors before corresponding with the AOCR.

Those who wish to photocopy articles should contact the AOCR Publications Department [Telephone: (215) 440-9300; FAX: (215) 440-9354].

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Clinical Cancer Research is abstracted and/or indexed in Cancer Lit, Chemical Abstracts, and Current Contents (Clinical Medicine).

Clinical Cancer Research (ISSN 1078-0432) is published monthly by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for $40 annually for members and $95 for individual nonmembers. Clinical Cancer Research is only available to institutions as a combined subscription with Cancer Research. The combined 1996 institutional subscription price of $595 includes $90 for a subscription to Clinical Cancer Research. Second-class postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to Clinical Cancer Research, P.O. Box 3000, Denville, NJ 07834. Copyright 1996 by the American Association for Cancer Research, Inc. Printed on acid-free paper in the U.S.A.
87th ACR Annual Meeting
Preliminary Program

(Saturday, April 20, 1996)

11:00 a.m.-8:00 p.m. Registration

12:00 noon-6:30 p.m. Educational Sessions (Sessions are two hours in length. Exact schedule to be announced.)

ED1 Human Pharmacogenetics: Molecular Mechanisms and Clinical Relevance in Cancer Treatment, William E. Evans, Denis M. Grant, Robert B. DiSario


ED3 The Cell Cycle, Michael B. Kastan, William G. Kaelin, Jr., Chi Van Dang

ED4 Beyond the Human Genome Project: Technical Aspects of Genomic Characterization and Its Application to Cancer Research, Glen A. Evans

ED5 Combinatorial Library Methods for Basic Research and Drug Discovery, Sydney E. Salmon, Kit S. Lam, George Smith, Victor Krchnak


2:00 p.m.-6:00 p.m. Methods Workshops (Separate registration required)

WK1 Quantitative Biology and Pharmacodynamics, Robert C. Jackson, Robert L. Dedrick, Mark J. Ratain, William R. Greco


6:30 p.m.-8:30 p.m. Women in Cancer Research Guest Lecture and Reception. Washington, DC Renaissance Hotel

8:00 p.m.-10:00 p.m. Opening Mixer. Washington, DC Renaissance Hotel

(Sunday, April 21, 1996)

7:00 a.m.-4:00 p.m. Registration

7:00 a.m.-8:00 a.m. Sunrise Sessions

SUN1 Diane F. Birt: Mechanisms of Dietary Prevention of Cancer

SUN2 William S. Dalton: Challenges in Bone Marrow Transplantation

SUN3 Ronald B. Herberman: Natural Killer Cells

SUN4 Rakesh K. Jain: Tumor Pathophysiology: Role in Delivery of Molecules, Particles, and Cells

SUN5 Lovell A. Jones: Estrogens and Breast Cancer

SUN6 Stanley J. Korsmeyer: Apoptosis: Regulation and Oncogenesis

SUN7 Fumio I. Olopade: Chromosomal Deletions and Cancer: Recent Advances in Mapping Techniques

7:00 a.m.-8:00 a.m. State Legislative Committees Meeting. Grand Hyatt Washington Hotel

8:00 a.m.-12:00 noon Poster Discussion Sessions

IM1 Antigens, Vaccines, and Monoclonal Antibodies

EN1 Breast Cancer I

MB1 Gene Expression in Breast Cancer I

8:00 a.m.-12:00 noon Poster Sessions

MB2 Viral Oncogenesis I

MB3 Transcription Factors

MB4 Lung and Skin Cancer

ET2 Pharmacokinetics and Toxicology

ET3 Reversal of P-Glycoprotein Resistance by Small Molecules

ET4 Gene Therapy I - Tumor Directed Therapies

ET5 Genetic Determinants of Chemosensitivity

IM2 Cytokines and Tumor Immunity I

EN2 Prostate Cancer I

CI2 Supportive Care and Tumor Biology

CG2 Chemical Carcinogenesis

CG3 Genetic and Cytogenetic Alterations in Human Tumor Cells

BL2 Invasion and Motility

BL3 Genetic Changes and Altered Gene Expression During Tumor Progression

EP1 Genetic Epidemiology - Prevention and Susceptibility

EP2 Retinoids, Antioxidants, and NSAIDS

8:15 a.m.-11:45 a.m. Minisymposia

CI1 Leukemia and Lymphoma

CG1 Biomarkers of Chemical Exposure

ET1 DNA Topoisomerase I and Camptothecins

BL1 Mechanisms of Apoptosis

8:15 a.m.-11:30 a.m. Plenary Session

The Progress and Promise of Cancer Research: A Celebration of the Twenty-fifth Anniversary of the National Cancer Act, Joseph R. Berenson, Harold E. Varmus, Arnold J. Levine, Susan Band Horwitz, Lloyd J. Old, Paul Talalay, James F. Holland

11:45 a.m.-12:45 p.m. 35th Clovis Award Lecture

Robert A. Weinberg. Control of Proliferation by the Cell Cycle Clock

12:30 p.m.-5:00 p.m. Commercial Exhibit Show

1:00 p.m.-2:00 p.m. Controversy Session 1

Are Antioxidants Useful in Cancer Prevention? Waun Ki Hong, Frank L. Meyssken, Jr., E. Robert Greenberg

1:00 p.m.-2:00 p.m. Controversy Session 2


1:00 p.m.-5:00 p.m. Poster Discussion Sessions

BL4 Genes Involved in Invasion and Metastasis

ET7 DNA Repair and Its Inhibition

CG4 Oxygen Radicals

1:00 p.m.-5:00 p.m. Poster Sessions

MB6 Signal Transduction

MB7 Gene Regulation in Breast Cancer

MB8 Gene Regulation

ET8 Expression of Drug Resistance Genes in Human Tumors

ET9 P-Glycoprotein, MRP, and Other Mechanisms of Multidrug Resistance

ET10 ras/nraf Directed Therapy

ET11 Pyrimidine Antimetabolites

IM3 Cytokines and Tumor Immunity II

EN3 Growth Factors and Cell Surface Receptors

C4 Phase II/III Studies

CG5 Animal Models

BL5 Growth Factors and Cytokines

BL6 Biological Aspects of Drug Resistance
MONDAY, APRIL 22, 1996

7:00 a.m. - 8:00 a.m. Sunrise Sessions
SUN8 Peggy J. Farnham: Nuclear Oncogenes: Effects on Cell Cycle Regulation and Neoplastic Transformation
SUN9 John G. Gribben: Quantitative PCR as a Tool to Detect Minimal Residual Disease in Leukemia and Lymphoma
SUN10 Stephen S. Hecht: Chemoprevention of Cancers Associated with Tobacco Use
SUN11 V. Craig Jordan: Antiestrogens
SUN12 Philip Livingston: Specific Immunotherapy of Melanoma
SUN13 John A. McLachlan: Environmental Carcinogens: Their Impact in Cancer
SUN14 Daniel Medina: Multistage Mammary Carcinogenesis

7:00 a.m. - 8:00 a.m. WICR Networking Session. Washington, DC Renaissance Hotel

8:00 a.m. - 11:00 a.m. Symposium
S6 Steroid Hormones: Breast and Prostate Cancer, Mylles A. Brown, Benita S. Katzenellenbogen, Donald P. McDonnell, Norman M. Greenberg, Roger L. Miesfeld
S7 Matrix Metalloproteinases and Their Inhibitors, Lynn M. Matrisian, Ruth J. Muschel, Motoharu Seiki, Yves DeClerck, Peter Brown

8:00 a.m. - 12:00 noon Poster Discussion Sessions
BL8 Apoptosis
MB9 DNA Repair
ET13 Biology of MRPs

8:00 a.m. - 12:00 noon Poster Sessions
BL9 Tumor Vasculature and Angiogenesis
BL10 Differentiation and Growth Inhibition
BL11 Regulation and Characterization of Cell Cycle Genes
IM5 Immunobiology
EN4 Nuclear Receptors and Signal Transduction
CI5 Clinical Pharmacology II
CG6 Molecular Responses to DNA Damage
CG7 Cell Culture and Animal Models
EP5 Cancer Biomarkers
ET14 Novel Topoisomerase Inhibitors
ET15 Kinase Directed Therapies
ET16 Novel Antitumor Agents I
ET17 Novel Antitumor Agents II
MB10 p53
MB11 Oncogenes
MB12 Gene Expression

8:15 a.m. - 11:45 a.m. Minisymposia
EP4 Mechanisms of Chemoprevention
IM4 Tumor Antigens and Effector Cell Response
ET12 Novel Drug Resistance Mechanisms
RR2 Radiation, Apoptosis, and the Cell Cycle

1:00 p.m. - 2:00 p.m. Fifth American Cancer Society Award Lecture
Lee W. Wattenberg, Prevention of Cancer: The Role of Chemoprevention for the General Population and for Individuals at High Risk Due to Genetic Defect or Other Factors

1:00 p.m. - 2:00 p.m. Controversy Session 3
Does Regional Chemotherapy Work? David S. Alberts, Maurie Markman, Michael J. O'Connell

1:00 p.m. - 5:00 p.m. Poster Discussion Sessions
CG8 Carcinogen Metabolism in Animals and Humans
BL13 Molecular Effectors of Tumor Progression
ET18 Antifolate and Thymidylate Synthase Inhibitors

1:00 p.m. - 5:00 p.m. Poster Sessions
BL14 Antinvasion or Metastasis Strategies
BL15 Behavior of Naturally Occurring Tumors and Model Systems
IM6 Immunomodulation
IM7 Modulation of T Cell Function
IM8 Modulation of Macrophage and NK/LAK Cell Function
CI7 Clinical Pharmacology - Pharmacokinetics
CG9 Metabolism and Activation of Carcinogens in Animal Models
CG10 Tumor Promotion/Progression
EN6 Breast Cancer II
ET19 Alkylating Agents and Platinum Analogues
2:15
6:00
RR
Investigations.

WEDNESDAY, APRIL 24, 1996

7:00 a.m.-2:00 p.m. Registration

7:00 a.m.-8:00 a.m. Sunrise Sessions
SUN22 Ernest C. Borden: Interferons in Cancer
SUN23 Richard A. Heyman: Transcription Factors As Therapeutic Targets
SUN24 Theodore S. Lawrence: Radiation Sensitization
SUN25 Eric K. Rowinsky: Drugs Which Interact with Microtubules: An Update
SUN26 Jeffrey Schlon: Tumor Vaccines
SUN27 Peter D. Senter: Prodrugs for Cancer Chemotherapy
SUN28 Martha R. Stampler: Culturing Normal and Transformed Human Epithelial Cells

8:00 a.m.-11:00 a.m. Symposia
S22 Cell Adhesion Receptors and the Cytoskeleton, Jun-Lin Guan and Rudolph L. Juliano, Thomas P. Stossel, Paul Polakis, Eva Ann Turley
S23 Drug Metabolizing Enzymes in Cancer Prevention and Therapy, Cecil B. Pickett, F. Peter Guengerich, Frank J. Gonzalez, Chung S. Yang
S24 The Cell Cycle and Damage Response Pathways: Potential Targets for Therapy, Stephen H. Friend, Frank McCormick, David Beach, James M. Roberts, Nick J. Dyson, Paul A. Marks

8:00 a.m.-12:00 noon Poster Discussion Sessions
EP9 Mutation Epidemiology and Biomarkers of Environmental Exposure
ET36 Therapy Directed Apoptosis
IM13 Cytokines and Tumor Immunity III

8:00 a.m.-12:00 noon Poster Sessions
EN8 Hormone Action, Hormone Synthesis, Metabolism, and Inhibitors
BL24 Apoptosis - Molecular Mechanisms II
BL25 Regulation of Cell Cycle Genes by Endogenous and Exogenous Factors
BL26 Extracellular Matrix, Signaling, and Adhesion
CG16 DNA Adducts
CG17 Exposure Biomarkers
CI14 Clinical Tumor Biology II
EP10 Effects of Chemopreventive Agents on Carcinogen Metabolism and DNA Adducts

IM14 Monoclonal Antibodies: Immunoconjugates and Immunotherapy
MB26 Techniques in Molecular Biology
MB27 Enzymes and Isoenzymes
MB28 Gene Expression in Ovarian Cancer
ET37 Taxol
ET38 Gene Therapy II - Gene Transfer, Cell Cycle, and Other Studies
ET39 Pharmacodynamics
ET40 Glutathione and Other Drug Resistance Mechanisms

8:15 a.m.-11:45 a.m. Minisymposia
CI13 Phase I Trials
CG15 Signal Transduction in Tumor Progression
ET35 Human Gene Therapy: Early Trial Results and Promising New Leads
MB25 Microsatellite Instability

11:45 a.m.-12:45 p.m. 15th Cain Award Lecture
Kurt W. Kohn, Beyond DNA Crosslinking

1:00 p.m.-2:00 p.m. Controversy Session 4
Is p53/Rb Important for Therapeutic Outcome?, William F. Benedict, Carlos Cordon-Cardo, David Sidransky

Controversy Session 5
Should Genetic Testing Be Done on Patients to Assess Cancer Risk? Judy E. Garber

1:00 p.m.-5:00 p.m. Poster Discussion Sessions
EP11 Diet and Nutrition
ET42 Developing Effective Gene Therapy: Promising Strategies and Vectors
MB29 Retinoids and Differentiation

1:00 p.m.-5:00 p.m. Poster Sessions
EN10 Gynecological, Lung, and Genitourinary Cancers
RR4 Animal and Patient Studies with Radiation/Drug-Radiation Studies
BL28 Apoptosis - Clinical Implications
BL29 Signal Transduction II
CG18 Mutagenesis and Repair
CG19 Growth Factors and Signaling in Carcinogenesis
CI16 Clinical Tumor Biology III
IM15 Monoclonal Antibodies; Immunotoxins and Immunotherapy
MB30 Tumor Suppressor Genes III
MB31 Tumor Suppressor Genes IV
MB32 Gene Regulation and Expression
ET43 Regulation of P-Glycoprotein Expression
ET44 New Drugs II
ET45 Tumor Models and Methods of Drug Delivery
ET46 Liposomes and Drug Delivery Formulations
ET47 Experimental Drug Resistance

1:45 p.m.-5:15 p.m. Minisymposia
BL27 Novel Signaling Pathways and Crosstalk
CI15 Predictors of Response and Prognosis Markers in Solid Tumors
EN9 Prostate Cancer II
ET41 Alkylating Agents and Platinum Analogs II

2:15 p.m.-5:15 p.m. Symposium
S26 Genetic Predisposition to Cancer, Mark H. Skolnick, Francis S. Collins, Richard D. Kolodner, William B. Isaacs, Sean Tavtigian